PGP and liver dysplastic nodule: Compared to the effect of Cyp2C11, Cyp3A11, and Cyp2C37, we speculate that the changes in pharmacokinetic parameters of HQD in DN may be mainly mediated by the down-regulation of P-gp and BCRP expression, which results in an increase in the AUC and a decrease in the CLZ/F of astragaloside IV, glycyrrhizic acid, calycosin-7-O-β-D-glucoside, ononin, and the metabolites of aglycones.